Efranat
Uri Yogev
uri.yogev@nullefranat.com
+ 972-8-9724972
Efranat Ltd develops anti-cancer immunotherapy. The concept underlying the technology is to engage the body's own natural immune system, and harness it to fight disease. This immunotherapy is based on an activation mechanism of macrophages, one of the white blood cells group, against cancer in patients. The activating factor used for treatment is named GcMAF. The protein is prepared in vitro and is similar to the native MAF in healthy people.
This approach is based upon Professor Nobuto Yamamoto's innovative research and discoveries, over the last 30 years.
Get more BANG for your BUCK at industry events.
Aneeva's Event Optimization Service helps you drive sales and maximize ROI from industry events via pre-set sales meetings with targeted customers.